Atea Pharmaceuticals's Earnings Outlook
Portfolio Pulse from Benzinga Insights
Atea Pharmaceuticals (NASDAQ:AVIR) is set to release its latest quarterly earnings report on November 8, 2023. Analysts estimate an earnings per share (EPS) of $-0.48. The company's past performance shows a pattern of beating EPS estimates, which has sometimes led to an increase in share price. However, the stock has been down 32.7% over the last 52-week period.
November 07, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Atea Pharmaceuticals is expected to report an EPS of $-0.48. The company has a history of beating EPS estimates, which could potentially lead to a short-term increase in share price. However, the stock has been down 32.7% over the last 52 weeks.
Atea Pharmaceuticals has a history of beating EPS estimates, which could potentially lead to a short-term increase in share price. However, the overall trend for the stock has been negative over the past year, which could dampen any positive impact from the earnings report.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100